日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Characterization of cell states in biliary tract cancers identifies mechanisms of therapeutic resistance in a phase II trial of DKN-01/nivolumab

对胆道癌细胞状态的表征揭示了DKN-01/nivolumab II期临床试验中的治疗耐药机制

Park, Ryan J; Parikh, Milan; Pappas, Leon; Sade-Feldman, Moshe; Kulkarni, Anupriya S; Bi, Lynn; LaSalle, Thomas J; Galway, Aralee; Kuhlman, Caroline; Blaszkowsky, Lawrence S; Meyerhardt, Jeffrey A; Enzinger, Peter C; Biller, Leah; Allen, Jill N; Kagey, Michael H; Baum, Jason; Sirard, Cynthia; Duda, Dan G; Zhu, Andrew X; Abrams, Thomas A; Hacohen, Nir; Ting, David T; Mehta, Arnav; Goyal, Lipika

Treatment of Gemcitabine-Induced Thrombotic Microangiopathy Followed by Gemcitabine Rechallenge With Eculizumab

使用依库珠单抗治疗吉西他滨诱发的血栓性微血管病,随后进行吉西他滨再次挑战

Efe, Orhan; Goyal, Lipika; Galway, Aralee; Zhu, Andrew X; Niles, John L; Zonozi, Reza

Nivolumab in Advanced Hepatocellular Carcinoma: Safety Profile and Select Treatment-Related Adverse Events From the CheckMate 040 Study

纳武利尤单抗治疗晚期肝细胞癌:CheckMate 040 研究的安全性概况和部分治疗相关不良事件

Julien, Karen; Leung, Hiu Tung; Fuertes, Carmen; Mori, Megumi; Wang, Miao-Jen; Teo, Jocelyn; Weiss, Lisa; Hamilton, Sara; DiFebo, Holly; Noh, Yoon Jin; Galway, Aralee; Koh, Jane; Brutcher, Edith; Zhao, Huanyu; Shen, Yun; Tschaika, Marina; To, Yue-Yun

A Phase II and Biomarker Study of Sorafenib Combined with Modified FOLFOX in Patients with Advanced Hepatocellular Carcinoma.

索拉非尼联合改良FOLFOX方案治疗晚期肝细胞癌患者的II期生物标志物研究

Goyal Lipika, Zheng Hui, Abrams Thomas A, Miksad Rebecca, Bullock Andrea J, Allen Jill N, Yurgelun Matthew B, Clark Jeffrey W, Kambadakone Avinash, Muzikansky Alona, Knowles Michelle, Galway Aralee, Afflitto Anthony J, Dinicola Caroline F, Regan Eileen, Hato Tai, Mamessier Emilie, Shigeta Kohei, Jain Rakesh K, Duda Dan G, Zhu Andrew X